Last reviewed · How we verify
Utidelone Injection; capecitabine
At a glance
| Generic name | Utidelone Injection; capecitabine |
|---|---|
| Sponsor | Beijing Biostar Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases (PHASE2)
- Tolerability and Bioavailability of Utidelone Capsule in Patients With Advanced Solid Tumors (PHASE1)
- PK and Drug Interaction Study of Utidelone Plus Capecitabine in Patients With Advanced Breast Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: